Roxanne Cooksey1, Sinead Brophy2, Jonathan Kennedy2, Fabiola Fernandez Gutierrez2, Tim Pickles3, Ruth Davies3, Vincent Piguet3, Ernest Choy3. 1. Swansea University Medical School, Data Science, Swansea University, Swansea, United Kingdom. Electronic address: r.cooksey@swansea.ac.uk. 2. Swansea University Medical School, Data Science, Swansea University, Swansea, United Kingdom. 3. Division of Infection and Immunity, Cardiff University School of Medicine, Cardiff University, Cardiff, United Kingdom.
Abstract
OBJECTIVES: Increased cardiovascular risk in rheumatoid arthritis (RA) is well established. Examining traditional cardiovascular risk factors alone underestimates cardiovascular risk in RA. Systematic inflammation, measured by erythrocyte sedimentation rate or C-reactive protein is also a major risk factor. However, the contribution of traditional cardiovascular risk factors (such as obesity and hyperlipidaemia) compared to inflammation is uncertain in psoriatic arthritis (PsA) and RA. We examine the incidence of major adverse cardiac events (MACE) among patients with RA, PsA psoriasis, and controls adjusting for risk factors, inflammation and disease modifying anti-rheumatic drug treatment, to better define cardiovascular risk. METHODS: Using the Secure Anonymised Information Linkage databank, comprising routinely collected Welsh health data from 1999 to 2013, the incidence and first occurrence of a MACE in individuals with RA (n = 8650), PsA (n = 2128) and psoriasis (n = 24,630) compared to controls (n = 11,87,706) was investigated. RESULTS: Traditional cardiovascular risk factors are higher in RA, PsA and psoriasis than controls. After adjusting for these factors, additional cardiovascular risk was only significantly increased in female RA patients (HR = 1.3; 95% CI: 1.0-1.7; p = 0.05) and psoriasis (HR = 1.2; 95% CI: 1.0-1.4; p = 0.02) but not statistically significant for PsA (HR = 1.5; 95% CI: 0.9-2.5; p = 0.13). ESR and CRP were increased in patients with RA but not in patients with psoriasis. CONCLUSION: Additional increased cardiovascular risk was observed in female RA and psoriasis but not PsA. Systematic inflammation is higher in RA but not psoriasis, indicating that there are varying mediators of cardiovascular risk across these conditions.
OBJECTIVES: Increased cardiovascular risk in rheumatoid arthritis (RA) is well established. Examining traditional cardiovascular risk factors alone underestimates cardiovascular risk in RA. Systematic inflammation, measured by erythrocyte sedimentation rate or C-reactive protein is also a major risk factor. However, the contribution of traditional cardiovascular risk factors (such as obesity and hyperlipidaemia) compared to inflammation is uncertain in psoriatic arthritis (PsA) and RA. We examine the incidence of major adverse cardiac events (MACE) among patients with RA, PsA psoriasis, and controls adjusting for risk factors, inflammation and disease modifying anti-rheumatic drug treatment, to better define cardiovascular risk. METHODS: Using the Secure Anonymised Information Linkage databank, comprising routinely collected Welsh health data from 1999 to 2013, the incidence and first occurrence of a MACE in individuals with RA (n = 8650), PsA (n = 2128) and psoriasis (n = 24,630) compared to controls (n = 11,87,706) was investigated. RESULTS: Traditional cardiovascular risk factors are higher in RA, PsA and psoriasis than controls. After adjusting for these factors, additional cardiovascular risk was only significantly increased in female RApatients (HR = 1.3; 95% CI: 1.0-1.7; p = 0.05) and psoriasis (HR = 1.2; 95% CI: 1.0-1.4; p = 0.02) but not statistically significant for PsA (HR = 1.5; 95% CI: 0.9-2.5; p = 0.13). ESR and CRP were increased in patients with RA but not in patients with psoriasis. CONCLUSION: Additional increased cardiovascular risk was observed in female RA and psoriasis but not PsA. Systematic inflammation is higher in RA but not psoriasis, indicating that there are varying mediators of cardiovascular risk across these conditions.
Authors: Robin K Dore; Jenya N Antonova; Chakkarin Burudpakdee; Lawrence Chang; Magdaliz Gorritz; Mark C Genovese Journal: ACR Open Rheumatol Date: 2021-11-18
Authors: Isabela M Bensenor; Alessandra C Goulart; Alexandre C Pereira; André R Brunoni; Airlane Alencar; Raul D Santos; Márcio S Bittencourt; Rosa W Telles; Luciana Andrade Carneiro Machado; Sandhi Maria Barreto; Bianca de Almeida-Pititto; Carolina Porto Silva Janovsky; José Augusto Sgarbi; William R Tebar; Vandrize Meneghini; Fernando Barbosa Junior; Ana Cristina de Medeiros Ribeiro; Sandra Gofinet Pasoto; Rosa Maria R Pereira; Eloísa Bonfá; Aytan M Sipahi; Itamar de S Santos; Paulo A Lotufo Journal: Clinics (Sao Paulo) Date: 2022-04-06 Impact factor: 2.365
Authors: Katelynn M Wilton; Sara J Achenbach; Paras Karmacharya; Floranne C Ernste; Eric L Matteson; Cynthia S Crowson Journal: J Rheumatol Date: 2020-10-15 Impact factor: 5.346
Authors: Frances S Mair; Stefan Siebert; Ross McQueenie; Barbara I Nicholl; Bhautesh D Jani; Jordan Canning; Sara Macdonald; Colin McCowan; Joanne Neary; Susan Browne Journal: BMJ Open Date: 2020-11-23 Impact factor: 2.692
Authors: Peter C Taylor; Tsutomu Takeuchi; Gerd R Burmester; Patrick Durez; Josef S Smolen; Walter Deberdt; Maher Issa; Jorge Ross Terres; Natalia Bello; Kevin L Winthrop Journal: Ann Rheum Dis Date: 2021-10-27 Impact factor: 19.103